REPLIMUNE GROUP, INC. Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
REPLIMUNE GROUP, INC. (REPL) had Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss of $9.97 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets › Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss
us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss · last filed 2026-08-14
- 2026-06-30: Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss $9.97M.
- 2026-03-31: Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss $59.86M.
- 2025-12-31: Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss $146.06M.
- 2025-09-30: Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss $221.18M.
| Period end | Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss |
|---|---|
| 2026-06-30 | $9.97M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $59.86M 10-Q · filed 2026-08-14 |
| 2025-12-31 | $146.06M 10-Q · filed 2026-02-03 |
| 2025-09-30 | $221.18M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $305.93M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $372.38M 10-K · filed 2026-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |